Inflammation-related proteomic changes in response to amyloid and tau pathologies - Poster presentation - Biomarkers

Sep 30, 2026

Uploaded by Noah

Emerging evidence highlights neuroinflammation as a key driver in Alzheimer’s disease (AD) progression, particularly through inflammatory mechanisms linked to amyloid-β (Aβ) and tau deposition. The study aims to identify biomarkers reflecting brain inflammatory changes in AD by profiling immune-related proteins in cerebrospinal fluid (CSF) and plasma. Analyses relate protein levels to Aβ and tau PET measures within an AD continuum cohort and validate findings in independent cohorts.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages4

Reading Time10 min

AccessFree to download

Background

Methods

Results

Conclusion

DOI: 10. 1002/alz70856_106582 BIOMARKERS POSTER PRESENTATION BIOMARKERS (NON-NEUROIMAGING) Inflammation-related proteomic changes in response to amyloid and tau pathologies Ilaria Pola1 Nicholas J. Ashton2, 3, 4, 5, 6 Marco Antônio De Bastiani7 Luiza Santos Machado8 Guilherme Povala9 Wagner S. Brum 10 Nesrine Rahmouni 11, 12 Kübra Tan 1 Marisa N. Denkinger 13 Stijn Servaes 11, 12 Joseph Therriault 11, 12 Tharick A Pascoal9 Kaj Blennow 1, 14 Henrik Zetterberg 1, 15, 16, 17, 18, 19, 20 Eduardo R. Zimmer7, 21, 22 Pedro Rosa-Neto 11, 23 Andrea L. Benedet 1 1 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden 2 Centre forAge-Related Medicine, Stavanger University Hospital, Stavanger, Norway 3 Banner Alzheimer’s Institute, Phoenix, AZ, USA 4 King’s College London, London, United Kingdom 5 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Gothenburg, Sweden 6 NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, NHS Foundation, London, United Kingdom 7 Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil 8 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, VG, Sweden 9 University of Pittsburgh, Pittsburgh, PA, USA 10 Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil 11 McGill University, Montreal, QC, Canada 12 Montreal Neurological Institute, Montreal, QC, Canada Abstract Background: Emerging evidence underscores the importance of neuroinflammation in the progression of Alzheimer’s disease (AD) pathophysiology. Recent studies indicate the involvement of inflammatory mechanisms in amyloid-β (Aβ) and tau deposition in the brain. Due to the complexity of the immune responses and the intricate interplay between the peripheral and the central nervous systems, identifying biomarkers that reflect the brain inflammatory changes in AD has been challenging. With this study, we sought to characterize immune-related proteins in cerebrospinal fluid (CSF) and plasma, in relation toAβ and tau PET. Methods: Participants from the Translational Biomarker for Aging and Dementia Cohort (TRIAD) incorporating within the AD spectrum, and with available Aβ PET ([18 F]AZD4694) and tau PET ([18 F]MK6240), had plasma (n = 376) and CSF (n = 277) samples analyzed with the NULISA technology (Alamar Biosciences®). A total of 309 inflammation-related proteins were selected and included in our analysis. Validation cohorts were used to generalize the results: ADNI had CSF samples (n = 384) analyzed with the SomaScan technology (SomaLogic® ); and BBDP had plasma samples (n = 253) analyzed with NULISA technology (Alamar Biosciences® ). Standardized (Std)β coefficients from linear models relating Aβ - and tau-PET SUVR (both included as independent variables) to the CSF and plasma protein levels. Models included age and sex and as covariates. Results: Several proteins exhibit distinct patterns in relation toAβ and tau pathologies. Notably, specific proteins show strong positive associations with global Aβ-PET levels, This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association. Alzheimer’s Dement. 2025;21(Suppl. 2):e106582. [https://doi.org/10.1002/alz70856_106582](https://doi.org/10.1002/alz70856_106582) wi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz) 1of4 BIOMARKERS 13 Banner Sun Health Research Institute, Sun City, AZ,

FAQs

What biological process the study focuses on in Alzheimer’s disease?

The study focuses on neuroinflammation and how immune-related proteins reflect inflammatory changes associated with amyloid-β and tau pathology in Alzheimer’s disease.

How were inflammation-related proteins measured and analyzed?

Inflammation-related proteins were selected and analyzed in cerebrospinal fluid and plasma using NULISA technology, with validation cohorts using SomaScan or NULISA depending on the dataset. Linear models related Aβ- and tau-PET SUVR to protein levels while adjusting for age and sex.

What did the results show about protein associations with amyloid and tau PET?

The results identified proteins with distinct association patterns: some were positively linked to global Aβ-PET independent of tau-PET, while others were positively linked to global tau-PET independent of Aβ-PET. Validation in ADNI and BBDP supported these findings and additional analyses suggested protein changes along disease pseudo-time.

Sep 30, 2026

Uploaded by Noah